Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 8th:
S&P Global Inc. (SPGI - Free Report) : This provider of independent ratings, benchmarks and data, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.3% over the last 60 days.
S&P Global has a PEG ratio 1.94, compared with 2.16 for the industry. The company possesses a Growth Score of A.
Cigna Corporation (CI - Free Report) : This health services organization, which carries a Zacks Rank #1 (Strong Buy), has witnessed the Zacks Consensus Estimate for its current year earnings rising 0.3% over the last 60 days.
Cigna has a PEG ratio 1.44, compared with 2.83 for the industry. The company possesses a Growth Score of A.
Copart, Inc. (CPRT - Free Report) : This vehicle remarketing services provider, which carries a Zacks Rank #1 (Strong Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.8% over the last 60 days.
Copart has a PEG ratio 1.42, compared with 1.84 for the industry. The company possesses a Growth Score of A.
Lam Research Corporation (LRCX - Free Report) : This semiconductor processing equipment manufacturer, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings rising 0.1% over the last 60 days.
Lam Research has a PEG ratio 0.90, compared with 1.24 for the industry. The company possesses a Growth Score of A.
See the full list of top ranked stocks here
Learn more about the Growth score and how it is calculated here.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 8th:
S&P Global Inc. (SPGI - Free Report) : This provider of independent ratings, benchmarks and data, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.3% over the last 60 days.
S&P Global has a PEG ratio 1.94, compared with 2.16 for the industry. The company possesses a Growth Score of A.
Cigna Corporation (CI - Free Report) : This health services organization, which carries a Zacks Rank #1 (Strong Buy), has witnessed the Zacks Consensus Estimate for its current year earnings rising 0.3% over the last 60 days.
Cigna has a PEG ratio 1.44, compared with 2.83 for the industry. The company possesses a Growth Score of A.
Copart, Inc. (CPRT - Free Report) : This vehicle remarketing services provider, which carries a Zacks Rank #1 (Strong Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.8% over the last 60 days.
Copart has a PEG ratio 1.42, compared with 1.84 for the industry. The company possesses a Growth Score of A.
Lam Research Corporation (LRCX - Free Report) : This semiconductor processing equipment manufacturer, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings rising 0.1% over the last 60 days.
Lam Research has a PEG ratio 0.90, compared with 1.24 for the industry. The company possesses a Growth Score of A.
See the full list of top ranked stocks here
Learn more about the Growth score and how it is calculated here.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on LRCX - FREE
Get the latest research report on CI - FREE
Get the latest research report on CPRT - FREE
Get the latest research report on SPGI - FREE